Earnings summaries and quarterly performance for INSMED.
Executive leadership at INSMED.
Board of directors at INSMED.
Research analysts who have asked questions during INSMED earnings calls.
JF
Jessica Fye
JPMorgan Chase & Co.
9 questions for INSM
Also covers: ALKS, ALNY, AMRN +23 more
RB
Ritu Baral
TD Cowen
9 questions for INSM
Also covers: ACAD, ALNY, ATAI +11 more
Jason Zemansky
Bank of America
8 questions for INSM
Also covers: ABOS, BBIO, CYTK +5 more
JS
Joseph Schwartz
Oppenheimer
8 questions for INSM
Also covers: ASND, AUPH, BMRN +14 more
Vamil Divan
Guggenheim Securities
8 questions for INSM
Also covers: ABBV, ABSI, ANIP +7 more
AN
Andrea Newkirk
Goldman Sachs
6 questions for INSM
Also covers: ABCL, ALKS, ARWR +9 more
Graig Suvannavejh
Mizuho Securities
6 questions for INSM
Also covers: ADAP, ADVM, ALEC +12 more
Jennifer Kim
Cantor Fitzgerald
6 questions for INSM
Also covers: BLTE, CPRX, EYPT +1 more
MS
Maxwell Skor
H.C. Wainwright & Co.
6 questions for INSM
Also covers: ASND, AVIR, CRNX +4 more
Liisa Bayko
Evercore ISI
5 questions for INSM
Also covers: ALT, BCRX, IPHA +7 more
NG
Nicole Germino
Truist Securities
5 questions for INSM
Also covers: CRIS, GILD, SGMO +1 more
SW
Stephen Willey
Stifel Financial Corp.
4 questions for INSM
Also covers: ABCL, CELC, CGEN +11 more
Andy Chen
Wolfe Research, LLC
3 questions for INSM
Also covers: ARGX, CRNX, IMVT +7 more
Gavin Clark-Gartner
Evercore ISI
3 questions for INSM
Also covers: ACRS, ARGX, ASND +12 more
JH
Jeff Hung
Morgan Stanley
3 questions for INSM
Also covers: ACAD, ALEC, BHVN +10 more
Leonid Timashev
RBC Capital Markets
3 questions for INSM
Also covers: ADCT, ALKS, AXSM +10 more
Matthew Phipps
William Blair
3 questions for INSM
Also covers: ABBV, AGEN, AMGN +8 more
OB
Olivia Brayer
Cantor
3 questions for INSM
Also covers: AMGN, AUPH, BMRN +9 more
SW
Stephen Willey
Stifel
3 questions for INSM
Also covers: ABCL, ABEO, CGEN +9 more
AT
Andrea Tan
Goldman Sachs
2 questions for INSM
Also covers: ABCL, ARWR, DAWN +3 more
AV
Ash Verma
UBS
2 questions for INSM
Also covers: ACAD, ALVO, AVDL +8 more
Ben Burnett
Stifel
2 questions for INSM
Also covers: ALKS, ALLO, FATE +2 more
CH
Chong Hun
UBS
2 questions for INSM
Clara Dong
Jefferies
2 questions for INSM
Also covers: AUTL, HRTX, LEGN +2 more
LT
Lena Times
RBC Capital Markets
2 questions for INSM
LW
Leon Wang
Barclays
2 questions for INSM
SL
Sam Long
Mizuho
2 questions for INSM
AW
Adam Walsh
Stifel, Nicolaus & Company, Inc.
1 question for INSM
Also covers: PTGX
Alex
Citigroup
1 question for INSM
Also covers: CYTK, DUK, FUL +5 more
AC
Andy Chan
Wolfe Research
1 question for INSM
Also covers: IMVT, IONS
AC
Andy Chin
Wolfe Research
1 question for INSM
AH
Andy Hsieh
William Blair & Company
1 question for INSM
Also covers: ALT, BYSI, CRDF +8 more
B
Brandon
Wolfe Research
1 question for INSM
Brandon Frith
Wolfe Research, LLC
1 question for INSM
Also covers: INCY, NTLA, ROIV
GS
Greg Silvanouve
Mizuho
1 question for INSM
Also covers: EYPT
J
Jasmine
Barclays
1 question for INSM
JZ
Jason Zemanski
Bank of America Securities
1 question for INSM
JS
Jin Shi
Wells Fargo
1 question for INSM
JS
Joe Schwartz
Leerink Partners
1 question for INSM
Also covers: BMRN, CRNX, KALV +3 more
Josh
Barclays
1 question for INSM
Also covers: ABEO, DAN, TWST
Kelly Shi
Jefferies
1 question for INSM
Also covers: ADCT, AGEN, ALDX +17 more
LT
Leonid Tamesha
RBC Capital Markets
1 question for INSM
TH
Trung Ho
UBS
1 question for INSM
TH
Trung Huynh
UBS Group AG
1 question for INSM
Also covers: ABBV, ABOS, AMGN +5 more
Recent press releases and 8-K filings for INSM.
Definium Therapeutics Reports Full-Year 2025 Results and Clinical Progress
INSM
Earnings
Guidance Update
New Projects/Investments
- Definium Therapeutics reported full-year 2025 financial results, ending the year with $411.6 million in cash, cash equivalents and investments as of December 31, 2025, which is expected to fund operations into 2028. This includes approximately $259 million in gross proceeds from an equity financing completed in Q4 2025.
- The company provided updates on its Phase 3 clinical programs for DT120 ODT: the MDD Emerge study is fully enrolled with topline data anticipated in late Q2 2026, and the GAD Voyage study is approximately 80% enrolled with topline data anticipated in early Q3 2026.
- For the full year 2025, Research and Development expenses increased to $117.7 million from $65.3 million in 2024, and the net loss was $(183.8) million, or $(2.06) per common share.
1 day ago
Insmed Reports Strong BRINSUPRI Launch and Provides 2026 Revenue Guidance
INSM
Earnings
Guidance Update
Product Launch
- BRINSUPRI achieved $144.6 million in net revenue in its first full quarter of launch in Q4 2025. Insmed expects BRINSUPRI revenue to be at least $1 billion in 2026, contributing to total company revenue in 2026 being more than double that of 2025.
- The company reported approximately $1.4 billion in cash, cash equivalents, and marketable securities as of the end of 2025 and is confident in achieving cash flow positivity without needing to raise additional capital.
- ARIKAYCE showed significant acceleration in Europe and Japan in 2025, with Japan contributing over a quarter of global revenues and growing 40% compared to 2024. Results from the Phase III ENCORE trial for ARIKAYCE are expected in March or April 2026, which could expand its addressable market from 30,000 to over 200,000 patients.
- Insmed believes BRINSUPRI has a peak sales estimate above $5 billion for its initial indication, with potential for significant upside from identifying undiagnosed bronchiectasis patients within COPD and asthma populations.
Feb 19, 2026, 1:00 PM
Insmed Reports Strong BRINSUPRI Launch and Provides 2026 Revenue Guidance
INSM
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Insmed announced that BRINSUPRI generated $144.6 million in net revenue in its first full quarter (Q4 2025) and provided 2026 revenue guidance of at least $1 billion for the therapy. The company anticipates total revenue in 2026 to be more than double the revenue produced in 2025, with ARIKAYCE contributing an expected $450 million-$470 million.
- The company ended 2025 with approximately $1.4 billion in cash, cash equivalents, and marketable securities and expressed confidence in achieving cash flow positivity without needing to raise additional capital.
- Key pipeline developments include TPIP receiving orphan drug designation for pulmonary arterial hypertension, the acquisition of INS1148, and the entry of two new gene therapies for DMD and ALS into the clinic.
Feb 19, 2026, 1:00 PM
Insmed Reports Strong Q4 2025 BRINSUPRI Launch and Issues Robust 2026 Revenue Guidance
INSM
Earnings
Guidance Update
Product Launch
- BRINSUPRI's net revenue in its first full quarter (Q4 2025) was $144.6 million, exceeding initial expectations.
- Insmed projects BRINSUPRI revenue of at least $1 billion in 2026 and anticipates total company revenue in 2026 to be more than double that of 2025, driven by BRINSUPRI and continued strong performance from ARIKAYCE.
- The company reported approximately $1.4 billion in cash, cash equivalents, and marketable securities at the end of 2025 and expects to achieve cash flow positivity for its base business without needing to raise additional capital, though it may seek capital for strategic business development.
- Insmed is actively working to expand BRINSUPRI's addressable market by identifying undiagnosed bronchiectasis in COPD and asthma patients and is advancing its pipeline, including TPIP in Phase III for PAH.
Feb 19, 2026, 1:00 PM
INSMED Announces Q4 2025 Results and Strong 2026 Revenue Guidance
INSM
Earnings
Guidance Update
Product Launch
- INSMED reported Total Revenues of $263.8 million for Q4 2025, compared to $104.4 million in Q4 2024, and an Operating Loss of $(319.7) million for Q4 2025.
- The U.S. launch of BRINSUPRI generated approximately $144.6 million in net revenues during Q4 2025.
- For the full year 2025, ARIKAYCE achieved $433.8 million in worldwide revenues, with U.S. revenues contributing $280.3 million.
- The company anticipates full-year 2026 total company revenues to more than double, with BRINSUPRI revenues projected to be at least $1 billion and ARIKAYCE revenues between $450 million and $470 million.
- As of December 31, 2025, INSMED maintained a strong capital position with approximately $1.4 billion in cash, cash equivalents, and marketable securities.
Feb 19, 2026, 1:00 PM
Insmed Reports Q4 and Full-Year 2025 Financial Results and Provides 2026 Guidance
INSM
Earnings
Guidance Update
Product Launch
- Insmed reported total company revenues of $606.4 million for full-year 2025, alongside a net loss of $1,276.8 million, or $6.42 per share.
- For full-year 2026, the company anticipates BRINSUPRI revenues of at least $1 billion and ARIKAYCE revenues between $450 million and $470 million, implying total company revenues of at least $1.45 billion.
- BRINSUPRI generated $144.6 million in revenues for Q4 2025 and $172.7 million for full-year 2025 after its U.S. commercial launch in August 2025.
- ARIKAYCE revenues reached $119.2 million for Q4 2025 and $433.8 million for full-year 2025, marking 19% annual growth.
- Insmed ended 2025 with approximately $1.4 billion in cash, cash equivalents, and marketable securities.
Feb 19, 2026, 12:01 PM
Insmed Reports Full-Year 2025 Financial Results and Provides 2026 Guidance
INSM
Earnings
Guidance Update
Product Launch
- Insmed reported total company revenues of $606.4 million for Full-Year 2025, with ARIKAYCE revenues at $433.8 million (representing 19% annual growth) and BRINSUPRI revenues at $172.7 million. The company also reported a net loss of $1,276.8 million, or $6.42 per share, for Full-Year 2025.
- As of December 31, 2025, Insmed had approximately $1.4 billion of cash, cash equivalents, and marketable securities.
- For Full-Year 2026, Insmed anticipates BRINSUPRI revenues to be at least $1 billion and ARIKAYCE revenues in the range of $450 million to $470 million.
- Key product developments include the European Commission's approval of BRINSUPRI in November 2025 and the FDA's Orphan Drug Designation for Treprostinil Palmitil for Pulmonary Arterial Hypertension (PAH) in January 2026.
Feb 19, 2026, 12:00 PM
Insmed Provides 2026 Revenue Guidance and Updates on Product Performance and Pipeline
INSM
Guidance Update
Product Launch
New Projects/Investments
- Insmed provided Full-Year 2026 revenue guidance of at least $1 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE.
- BRINSUPRI achieved ~$144.6 million in U.S. Net Revenues in Q4 2025 following its U.S. approval and launch, with the Phase 3 ASPEN study demonstrating statistical significance on both 10 mg and 25 mg doses.
- ARIKAYCE reported $119.2 million in worldwide revenue for Q4 2025 and $433.8 million for FY 2025, with a Phase 3 ENCORE topline readout expected in March/April 2026.
- The company anticipates several clinical catalysts in the next 18+ months, including the Phase 2b CEDAR readout for Brensocatib in Hidradenitis Suppurativa in Q2 2026 and positive Phase 2a results for TPIP in PH-ILD showing a clear improvement in 6MWD (P=0.003).
Feb 18, 2026, 12:00 PM
Insmed Faces Investor Investigation Following Discontinued Drug Development
INSM
Legal Proceedings
- Pomerantz LLP is investigating Insmed Incorporated for potential securities fraud or other unlawful business practices on behalf of its investors.
- The investigation follows Insmed's announcement on December 17, 2025, that its Phase 2b BiRCh study of brensocatib failed to meet its primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development.
- Following this news, Insmed's stock price fell $31.91 per share, or 16.08%, to close at $166.55 per share on December 18, 2025.
Jan 22, 2026, 3:00 PM
Insmed Faces Investigation Following Failed Drug Trial
INSM
Legal Proceedings
New Projects/Investments
- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (INSM) concerning potential securities fraud or unlawful business practices by the company's officers and/or directors.
- This investigation follows Insmed's announcement on December 17, 2025, that its Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development.
- Following this news, Insmed's stock price fell $31.91 per share, or 16.08%, to close at $166.55 per share on December 18, 2025.
Jan 15, 2026, 3:00 PM
Fintool News
In-depth analysis and coverage of INSMED.
Quarterly earnings call transcripts for INSMED.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more